5:29 PM
Dec 13, 2013
 |  BC Extra  |  Politics & Policy

IMI launching project for adaptive Alzheimer's trial

During the G8 Dementia Summit, the EU's Innovative Medicines Initiative (IMI) unveiled a EUR 53 million ($72.7 million) project (EPOC-AD) aimed at developing an adaptive proof-of-concept trial for Alzheimer's disease (AD) drug candidates. IMI said the aim is to conduct a trial to efficiently identify treatments or combinations "with sufficient promise" at preventing or halting the progression of...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >